A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers

Inclusion Criteria

• •Male or female with a diagnosis of hemophilia A
• •Previously or currently treated with damoctocog alfa pegol for at least 6 months.
• •Treated with damoctocog alfa pegol per the US approved label to include:
• •* Aged ≥12 years at the time of damoctocog alfa pegol treatment initiation
• •* Previously treated for hemophilia A with an FVIII replacement therapy other than damoctocog alfa pegol
• •* Treatment modality of on-demand, prophylactic, intermittent prophylaxis or a combination thereof
• •Have data in the medical record at the participating site as follows:
• •* For a minimum of 6 months prior to the damoctocog alfa pegol initiation date
• •* For a minimum of 6 months post-damoctocog alfa pegol initiation date AND the patient was receiving treatment with damoctocog alfa pegol during this 6-month follow-up period AND this data is dated prior to the central institutional review board (IRB) approval date for the study
• •* To include the FVIII replacement therapy most recently received prior to the initiation of damoctocog alfa pegol
• •For patients in the prospective cohort
• •* Signed informed consent
• •* Current treatment with damoctocog alfa pegol or discontinued use of damoctocog alfa pegol within 3 months prior to the date of enrollment into the retrospective cohort.